fulvestrant has been researched along with lapatinib in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 8 (61.54) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Goldberg, GL; Hazan, R; Horwitz, SB; Hou, JY; McDaid, HM; Rodriguez-Gabin, A; Samaraweera, L; Samaweera, L | 1 |
| Mehta, A; Tripathy, D | 1 |
| Fu, X; Giuliano, M; Klinowska, T; Morrison, G; Nanda, S; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Wang, T | 1 |
| Barry, WT; Blackwell, KL; Burstein, HJ; Chew, HK; Cirrincione, CT; Hudis, CA; Lake, DE; Ma, C; Tolaney, SM; Winer, EP | 1 |
| Hu, Y; Lee, S; Li, L; Lin, L; Schiff, R; Tan, Y; Veeraraghavan, J; Wang, X; Wang, XS | 1 |
| Burdaeva, O; Gradishar, WJ; Hegg, R; Im, SA; Iwata, H; Izquierdo, MA; Johnston, SRD; Kenny, S; Kurteva, G; Park, IH; Press, MF; Sarp, S; Simon, SD; Tjulandin, S; Williams, LS | 1 |
| Fujii, M; Fujimoto, Y; Haeno, H; Hakozaki, Y; Kashima, Y; Kobayashi, SS; Morita, TY; Mukohara, T; Ohashi, A | 1 |
| Adamczyk-Grochala, J; Błoniarz, D; Lewińska, A; Wnuk, M; Wołowiec, S; Wróbel, K | 1 |
| Acconcia, F | 1 |
| Belka, GK; Chen, S; Chodosh, LA; DeMichele, A; Makhlin, I; Mesaros, C; Pan, TC; Pant, DK; Paul, MR; Sreekumar, A; Sterner, CJ; Wang, D; Xu, P | 1 |
| Szymaszek, Ż; Twardowska, M; Uram, Ł; Walczak, M; Wołowiec, S; Wróbel, K | 1 |
2 review(s) available for fulvestrant and lapatinib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
2 trial(s) available for fulvestrant and lapatinib
| Article | Year |
|---|---|
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Hormones; Humans; Lapatinib; Middle Aged; Postmenopause; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2014 |
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Lapatinib; Middle Aged; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab | 2021 |
9 other study(ies) available for fulvestrant and lapatinib
| Article | Year |
|---|---|
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Benzamides; Carcinoma; Cell Line, Tumor; Diphenylamine; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Nude; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Lapatinib; Mice; Mice, Nude; Oncogene Proteins, Fusion; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Fulvestrant; Gene Expression; Humans; Lapatinib; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; RNA-Binding Proteins; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Lapatinib- and fulvestrant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dendrimers; Female; Fulvestrant; Humans; Lapatinib | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |
PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.
Topics: Animals; Drug Resistance, Neoplasm; Estrogens; Fulvestrant; Lapatinib; Mice; Neoplasm Recurrence, Local; Receptor, ErbB-2; Receptors, Progesterone | 2023 |
Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment.
Topics: Animals; Caenorhabditis elegans; Carcinoma, Non-Small-Cell Lung; Dendrimers; Fulvestrant; Glioma; Humans; Lapatinib; Lung Neoplasms; Paclitaxel; Parasites | 2023 |